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Abstract
Introduction: At present, there is no reliable tool for predicting disease outcome in patients with rheumatoid
arthritis (RA). We previously demonstrated an association between specific baseline biomarkers/clinical measures
including matrix metalloproteinase-3 (MMP-3) and 2-year radiographic progression in patients with RA. This study
further evaluates the predictive capability of these baseline variables with outcome extended over 8-years.
Methods: Fifty-eight of the original cohort (n = 118) had radiographic progression from baseline to mean 8.2-years
determined using the van der Heijde modified Sharp method. The contribution of each predictor variable towards
radiographic progression was assessed with univariate and multivariate analyses.
Results: Traditional factors (including erythrocyte sedimentation rate, C-reactive protein, anti-cyclic citrullinated peptide
(anti-CCP), and rheumatoid factor) and biomarkers of tissue destruction (including MMP-3, C-telopeptide of type II
collagen, cartilage oligomeric matrix protein, and tissue inhibitor of metalloproteinase 1) measured at baseline were
associated with radiographic progression at endpoint. Multivariate logistic regression identified anti-CCP seropositivity [OR
9.29, 95%CI: 2.29-37.64], baseline elevated MMP-3 [OR 8.25, 95%CI: 2.54-26.78] and baseline radiographic damage [OR 5.83,
95%CI: 1.88-18.10] as the strongest independent predictors of radiographic progression. A model incorporating these
variables had a predictive accuracy of 0.87, assessed using the area under the receiver operating characteristic curve.
Conclusion: In our cohort with onset of RA symptoms < 2-years, multivariate analysis identified anti-CCP status
and baseline MMP-3 as the strongest independent predictors of radiographic disease outcome at 8.2-years. This
finding suggests determination of baseline MMP-3, in conjunction with traditional serologic markers, may provide
additional prognostic information for patients with RA. Furthermore, these findings highlight the importance of
continued research into a broad range of biomarkers as potential predictors of joint damage.
Introduction
Current paradigms for management of patients with
rheumatoid arthritis (RA) dictate early aggressive therapy
in treatment-to-target strategies, aiming for remission of
symptoms [1]. In turn this prevents joint destruction and
associated co-morbidities, including cardiovascular com-
plications. A particular concern regarding these princi-
ples, however, is that some patients with RA may remit
with less aggressive treatment regimes, exposing a pro-
portion of patients to unnecessary medications and their
associated risks. Ideally it should be possible to study
baseline clinical characteristics and laboratory biomar-
kers of RA patients and prescribe according to a predic-
tive algorithm, so-called personalised medicine. Current
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algorithms, however, while predictive at a population
level, have insufficient power to guide treatment of the
individual patient [2].
Some baseline clinical and demographic markers (e.g.
female sex, older age, rheumatoid factor (RF), anti-cyclic
citrullinated peptide (anti-CCP) seropositivity, raised C-
reactive protein (CRP) or erythrocyte sedimentation rate
(ESR)) have been associated with a poor prognosis [3].
Surprisingly, none of these markers specifically reflect
ongoing destructive processes within bone and synovium.
Utilising observations from our own early arthritis cohort,
we previously reported a multivariate logistic regression of
various biomarkers at baseline. Our data suggested that a
model consisting of matrix metalloproteinase-3 (MMP-3)
and C-telopeptide of type II collagen (CTX-II) performed
better than ESR and CRP in predicting two-year radio-
graphic progression [4]. To examine the robustness of our
model over time we now report follow-up data over eight
years, additionally incorporating anti-CCP status. We
demonstrate that the measurement of serum MMP-3
levels at baseline enhances the predictive value of anti-
CCP in determining long-term radiographic outcome in
patients with RA. Hence, these findings suggest that
assessment of baseline MMP-3 and other biomarkers of
joint destruction, in conjunction with existing serological
markers and clinical measures, may provide additional
long-term prognostic information for patients with RA.
Materials and methods
Patients
The original cohort (n = 118, RA symptoms for less than
two years) presented between 1998 and 2000. Patient
demographics, inclusion criteria and study protocol were
described previously [4]. Sixty-two patients were revisited
in 2007, at mean follow up of 8.2 years. Four patients
were excluded with an alternative subsequent diagnosis
(three psoriatic arthritis and one systemic lupus erythe-
matosus). The remainder were either deceased (n = 16),
lost to follow up (n = 16) or declined participation (n =
24). Baseline CRP levels were higher in revisited patients
but there were no other significant differences in baseline
characteristics [see Additional data file 1]. Treatment
during the intervening period was decided according to
current local practice with sequential disease-modifying
anti-rheumatic drug (DMARD) mono or combination
therapy. Five patients (evenly split between low (n = 2)
and high (n = 3) progressor groups) subsequently
received anti-TNF biologic therapy. At the extension visit
serum was taken to determine anti-CCP status (Axis-
Shield Diagnostics Limited, Dundee, Scotland, UK). Ethi-
cal approval was obtained from Newcastle and North
Tyneside Research Ethics Committee and all patients
gave informed consent to take part in this extension
study.
Scoring of radiographs and division of cohort
Posteroanterior radiographs of the hands/wrists and feet
were collected at baseline and 8.2 years. One observer
(MH) was trained to apply the van der Heijde modified
Sharp scoring (SHS) method [5]. An intraclass correlation
coefficient of 0.91 was obtained assessing the same test set
(20 pairs of random radiographs) two weeks apart. Subse-
quently, radiographs were scored in chronological order
but blinded to identity. The baseline SHS was subtracted
from the 8.2-year SHS for each patient and a value repre-
senting radiographic progression obtained. Individuals
were allocated to low- or high-progressive groups based
on the median SHS change (Figure 1). Additional analysis
was performed using only the total SHS at 8.2 years to
determine the ‘absolute’ radiographic outcome. For this
analysis the cohort was sub-divided into non-progressors
and progressors using the lower quartile value derived
from the total SHS distribution (Figure 1).
Statistical analysis
A more detailed discussion regarding the use of non-para-
metric analyses was provided previously [4]. Briefly, asso-
ciation between baseline values of each potential predictor
and radiographic progression/absolute radiographic out-
come at 8.2 years, considered both as a continuous vari-
able (Spearman’s rank correlation) and as a binary variable
(Mann Whitney U test/Chi-square test/Student’s t-test),
was analysed. Univariate and forward stepwise (entry
probability = 0.05, removal probability = 0.1) logistic
regression were subsequently performed to assess the con-
tribution of each associated marker and to identify the
most predictive multivariate model, respectively. For this
analysis baseline variables were dichotomised into positive
or negative for autoantibodies, or high and low values
based on median values obtained in this study. The predic-
tive accuracy of each model was assessed using the area
under the receiver operating characteristic curve (ROC).
All statistical calculations were performed in Stata® (Stata-
Corp, College Station, Texas, USA).
Results
Division of the cohort based on radiographic progression
at 8.2 years
Fifty-eight (49%) patients from the original cohort were
analysed in the extension study. The median change in
SHS of 10.5 determined whether individuals were assigned
to the low (n = 29, SHS ≤10.5) or high progressor (n = 29,
> 10.5) group. Table 1 highlights baseline demographic
and clinical characteristics across the two groups.
Predictors of radiographic progression at 8.2 years
Mann Whitney analysis of traditional markers indicated
that high radiographic progressors had significantly ele-
vated measures of ESR, CRP, SHS and clinician’s global
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Figure 1 Cumulative distribution plots for outcome measures. (a) Change in Sharp’s score from baseline to 8.2-years follow up. (b) Total
Sharp’s score at 8.2-years follow up. The red line indicates the median and lower quartile cut-off points, respectively. RA, rheumatoid arthritis.
Table 1 Comparison of baseline demographic characteristics, clinical and biomarker measures in radiographic
progressor groups at 8.2 years
Low Progressors* High Progressors* Comparison SRC
Cohort characteristics (n = 29) (n = 29) z P$ rho P
Demographic
Female, no. (%) 22 (76%) 15 (52%) 3.66 0.100† - NA
Age, mean ± SD, years 52 ± 10 55 ± 12 0.97 0.334‡ - NA
Disease duration, days 260 (169, 412) 242 (146, 384) -0.59 0.555 - NA
DAS28 5.1 (4.0, 6.1) 6.2 (4.8, 6.8) 1.73 0.083 - NA
HAQ 1.3 (0.9, 2.0) 1.5 (1.0, 2.3) 0.90 0.370 - NA
No. DMARDs 2 (1, 2) 2 (2, 3) 1.81 0.070 - NA
MTX, no. (%) 8 (28) 21 (72) 11.66 0.001† - NA
Traditional measures
Total SHS 3 (0, 8) 16 (6, 28) 4.09 < 0.001 0.51 < 0.001
ESR, mm/hour 19 (11, 39) 34 (20, 50) 2.33 0.020 0.35 0.008
CRP mg/L 8 (5, 20) 34 (15, 65) 3.42 < 0.001 0.46 < 0.001
RF positive, no. (%) 19 (66%) 26 (90%) 4.86 0.056† 0.47 < 0.001
Anti-CCP +ve, no. (%) 14 (48%) 26 (90%) 11.60 0.001† 0.23 0.077
SJC 6 (2, 12) 10 (5, 15) 1.80 0.072 0.19 0.145
TJC 14 (5, 18) 15 (7, 18) 0.47 0.640 0.06 0.675
CGA on VAS, mm 24 (10, 57) 54 (38, 68) 2.48 0.013 0.34 0.010
PGA on VAS, mm 39 (27, 48) 47 (24, 65) 0.53 0.600 0.10 0.447
Biomarkers
MMP-3, ng/mL 51 (32, 86) 137 (86, 359) 3.83 < 0.001 0.46 < 0.001
CTX-II, μg/mmol 0.14 (0.08, 0.25) 0.36 (0.19, 0.57) 3.40 < 0.001 0.40 0.003
COMP, U/L 10 (8, 11) 13 (11, 16) 3.27 0.001 0.39 0.003
TIMP-1, ng/mL 647 (466, 719) 817 (669, 902) 2.34 0.019 0.29 0.029
*Except where indicated otherwise, values are median (25th and 75th percentiles). $Determined by Mann Whitney U test unless indicated otherwise. †Determined
by Fisher’s two-sided exact test. ‡Determined by Student’s t test.  Value taken at 8.2-year follow-up visit.
Anti-CCP, anti-cyclic citrullinated peptide; CGA, clinician’s global assessment; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; CTX-II, C-
telopeptide of type II collagen; DAS, disease activity score; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health
assessment questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; NA, not applicable; NS, not significant; PGA, patient’s global assessment; RF,
rheumatoid factor; SD, standard deviation; SHS, van der Heijde modified Sharp score; SJC, swollen joint count; SRC, Spearman’s rank correlation; TIMP-1, tissue
inhibitor of metalloproteinase 1; TJC, tender joint count; VAS, visual analogue score.
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assessment (CGA) at baseline compared with low pro-
gressors (Table 1). Extending our previous findings,
baseline levels of MMP-3, CTX-II, cartilage oligomeric
matrix protein (COMP), and tissue inhibitor of metallo-
proteinase 1 (TIMP-1) remained significantly higher in
high radiographic progressors. It should be noted that
there were significant correlations between levels of
these various markers [see Additional data file 2]. In
addition, baseline RF and anti-CCP status (determined
at 8.2 years) were more frequently positive in the highly
progressive patients. These findings were reproduced
using Spearman’s rank correlation analysis assessing
radiographic change as a continuous variable.
Biomarkers and clinical measures demonstrating asso-
ciation in the exploratory analyses were dichotomised
and further investigated by univariate logistic regression
(Table 2). Subsequently, stepwise logistic regression iden-
tified anti-CCP positivity, baseline elevated MMP-3 and
baseline SHS as the strongest independent predictors of
radiographic progression at 8.2 years (chi-squared =
14.97, P = 0.002). The predictive accuracy of this model,
as assessed by ROC, was superior to either factor alone
(combined area under the curve (AUC) = 0.87, anti-CCP
AUC = 0.71, MMP-3 AUC = 0.74, and SHS AUC = 0.71).
The positive predictive values (PPV) and negative predic-
tive values (NPV) of the combined model were 81% and
85%, respectively.
Predictors of absolute radiographic outcome at 8.2 years
Subanalyses were undertaken incorporating the patient
group deemed to have minimal radiographic progres-
sion. This utilised only the total SHS at 8.2 years
(median value = 26.5, lower quartile = 6, upper quartile
= 45.8). Patients were dichotomised into two groups,
termed non-progressors (n = 14) and progressors (n =
44), based on the lower quartile SHS. Univariate logistic
regression indicated traditional measures (ESR, CRP and
anti-CCP) and biomarkers (MMP-3 and COMP) were
also significant predictors of absolute radiographic out-
come (Table 2). Furthermore, stepwise logistic regres-
sion identified anti-CCP positivity and baseline elevated
MMP-3 as independent predictors of radiographic out-
come (chi-squared = 12.40, P = 0.002). The predictive
accuracy of this model was superior to either factor
alone (combined AUC = 0.84, anti-CCP AUC = 0.77,
and MMP-3 AUC = 0.68). The PPV and NPV of the
combined model were 87% and 64%, respectively.
Discussion
This extension study was conceived to further evaluate
the performance of selected biochemical/serological mar-
kers and routine clinical measures in predicting radio-
graphic disease outcome in a well-characterised RA
cohort. Apart from the inclusion of anti-CCP status, the
main methodological departure from the original study
was the use of the van der Heijde modified Sharp radio-
graph scoring system, which is more sensitive for detect-
ing temporal radiographic change in early RA [6]. The
change in SHS from baseline to 8.2 years was utilised to
reflect progression due to the underlying disease process
[7]. When considering the distribution of this measure
(Figure 1), patients were dichotomised into low and high
progressors using the median, an approach validated by
correlation analyses using change in SHS as a continuous
Table 2 Performance of baseline biomarkers as predictors of radiographic progression and absolute radiographic
outcome at 8.2 years with univariate analysis
Low vs high radiographic progression Absolute radiographic outcome, progressors vs non-
progressors
Baseline characteristics PPV (%) NPV (%) P OR (95% CI) PPV (%) NPV (%) P OR (95% CI)
Traditional measures
SHS (> 7┴) 71.43 70.00 0.002 5.83 (1.88, 18.10) - - - -
ESR (> 20 mm/hr∇) 60.00 65.22 0.064 2.81 (0.94, 8.39) 85.71 39.13 0.036 3.86 (1.09, 13.65)
CRP (> 5 mg/L∇) 59.52 75.00 0.024 4.41 (1.22, 16.00) 85.71 50.00 0.007 6.00 (1.62, 22.16)
Anti-CCP* (titer > 6 U/mL∇) 65.00 83.33 0.002 9.29 (2.29, 37.64) 90.00 55.56 0.001 11.25 (2.80, 45.16)
RF (titer > 40 U/mL∇) 57.78 76.92 0.036 4.56 (1.10, 18.86) 77.78 30.77 0.528 1.56 (0.39, 6.13)
CGA on VAS (> 49.00 mm┴) 60.71 60.00 0.118 2.32 (0.81, 6.64) 85.71 33.33 0.098 3.00 (0.82, 11.04)
Biomarkers of joint damage
MMP-3 (> 85.79 ng/mL┴) 75.00 73.33 < 0.001 8.25 (2.54, 26.78) 89.29 36.67 0.029 4.82 (1.18, 19.74)
CTX-II (> 0.20 μg/mmol┴) 66.67 66.67 0.016 4.00 (1.29, 12.40) 85.19 37.04 0.070 3.38 (0.91, 12.64)
COMP (> 11.20 U/L┴) 67.86 68.97 0.007 4.69 (1.54, 14.34) 89.29 37.93 0.024 5.09 (1.24, 20.92)
TIMP-1 (> 688.68 ng/mL┴) 65.52 65.52 0.020 3.61 (1.22, 10.66) 86.21 34.48 0.073 3.29 (0.89, 12.12)
* = Anti-CCP taken at 8.2-year follow-up visit. ┴ = indicates derived from median value in this study, ∇ = indicates derived from established normal value
95% CI, 95% confidence interval; Anti-CCP, anti-cyclic citrullinated peptide; CGA, clinician’s global assessment; COMP, cartilage oligomeric matrix protein; CRP, C-
reactive protein; CTX-II, C-telopeptide of type II collagen; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase-3; NPV, negative predictive value;
OR, odds ratio; PPV, positive predictive value; RF, rheumatoid factor; SHS, van der Heijde modified Sharp score; TIMP-1, tissue inhibitor of metalloproteinase 1;
VAS, visual analogue score.
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variable. Additionally the absolute radiographic prognosis
at 8.2 years was assessed to isolate the patient group that
might require less aggressive treatment and thus limit
exposure to therapies that carry potentially serious side
effect profiles.
Various baseline traditional factors including ESR, CRP
and RF, and biomarkers of cartilage and collagen break-
down including CTX-II, COMP and TIMP-1 were asso-
ciated with radiographic progression at 8.2 years,
consistent with other studies [3,4]. Overall, the strongest
predictors were anti-CCP (odds ratio (OR) = 9.29, 95%
confidence interval (CI) = 2.29 to 37.64) and MMP-3 (OR
= 8.25, 95% CI = 2.54 to 26.78), followed by baseline SHS
(OR = 5.83, 95% CI = 1.88 to 18.10). Similar findings were
observed in the subanalyses investigating predictors of
absolute radiographic prognosis. Baseline anti-CCP sero-
positivity has been associated previously with radiographic
progression [8,9]. Notably, the anti-CCP status in our
cohort was determined at follow up (8.2 years) rather than
baseline as it was not routinely available at the time of pri-
mary analysis. However, as other studies have shown posi-
tivity is generally stable over time, we have used this as a
surrogate of patients’ baseline status [10]. The predictive
accuracy of our model increased from 71% to 87% (PPV =
81% and NPV = 85%) with the addition of baseline MMP-
3 and baseline SHS to anti-CCP, an improvement of
potential clinical relevance. The inclusion of baseline
radiographic SHS score in our model contrasts with data
from the ASPIRE and ATTRACT biologic therapy trials,
in which baseline radiographic damage did not predict
outcome [11]. However, 82% to 99.1% of the ASPIRE and
ATTRACT participants had erosions at entry [11] com-
pared with 14% in our cohort, and it is now well estab-
lished that TNF blockade is more effective than traditional
DMARD therapy at inhibiting radiographic progression.
Furthermore, recent data from the BeSt study highlighted
seropositivity (anti-CCP or RF), baseline erosion score and
CRP as predictors of rapid radiographic progression [12].
Nonetheless, excluding baseline SHS from our model, to
provide more accessible prognostic information in the
clinic setting, had only a modest effect on its performance
(AUC = 0.83, PPV = 89% and NPV = 74%).
In our original study, stepwise logistic regression iden-
tified baseline MMP-3 with CTX-II as the strongest pre-
dictive model of radiographic outcome at two-years
follow up. As for other biomarkers investigated, CTX-II
remained a strong predictor of radiographic outcome at
8.2 years following univariate analysis; however, it
appeared to be no longer an independent predictor fol-
lowing multivariate analysis. This finding may reflect the
combination of reduced patient numbers and the corre-
lation between CTX-II and MMP-3 [see Additional data
file 2]. Indeed, it should be noted that several biomar-
kers performed similarly well in the univariate analysis
taking into account the wide confidence intervals.
Hence future studies, while attempting to validate and
assess the clinical value of our findings, should continue
to study a broad range of biomarkers as potential pre-
dictors of joint damage. The reduced size of the follow-
up cohort is a weakness of the current analysis but,
apart from baseline CRP (which was higher in revisited
patients), there were no other significant differences in
baseline characteristics between those patients who were
and were not revisited as part of the current study [see
Additional data file 1].
Notwithstanding the above caveats and in keeping
with results from the primary analysis, our eight-year
data continue to highlight MMP-3 as a strong predictor
of radiographic progression. MMPs play a pivotal role in
cartilage destruction and although they might provide a
means to monitor disease activity, response to treatment
and prognosis [13], this has yet to be fully established
[14]. Supporting evidence for the prognostic significance
of MMP-3 in RA, however, includes its expression in
RA synovial tissue and decreasing serum MMP-3 levels
following DMARD treatment [4,15]. Baseline MMP-3
levels have previously been shown to correlate with joint
destruction in studies with up to three years of observa-
tions [4,16-21] but, to our knowledge, ours is the first to
report that this predictive effect is maintained at eight
years of follow up.
Conclusions
We have demonstrated that the measurement of serum
MMP-3 levels at baseline adds to the predictive value of
anti-CCP in determining long-term radiographic out-
come in patients with RA. These findings support the
notion that MMP-3 influences important pathological
processes that are distinct from anti-CCP and are funda-
mental to the development of radiographic progression.
In addition, these findings indicate that assessment of
biomarkers that reflect joint destruction, such as base-
line MMP-3, in conjunction with existing serological
markers and clinical measures, may provide potentially
important prognostic information for patients with early
RA. We acknowledge the modest size of our cohort but
suggest that validation of these promising findings in
additional prospective studies is now warranted.
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non-participating subjects. Table presenting comparison analyses of
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subjects.
Additional file 2: Correlation between baseline biomarker measures.
Table presenting degree of correlation between novel biomarker
measures.
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